Prima BioMed Announces First Clinical Data From Combination of IMP321 With Anti-PD1
(firmenpresse) - SYDNEY, AUSTRALIA -- (Marketwired) -- 12/29/16 -- Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" or the "Company") today announced interim data for its TACTI-mel (Two ACTive Immunotherapeutics in melanoma) clinical trial program for IMP321 in unresectable or metastatic melanoma patients. The Database Safety Monitoring Board (DSMB) confirmed that IMP321 is safe and well tolerated at the first dose level when used in combination with a PD-1 blocking antibody and dose escalation can continue as planned.
In this first-in-man combination Phase I study, IMP321 is combined with the PD-1 checkpoint inhibitor pembrolizumab (KEYTRUDA®). Patients with unresectable or metastatic melanoma that had suboptimal or no responses to KEYTRUDA have been receiving IMP321 plus KEYTRUDA to help boost their immune responses and increase the tumour response rate to KEYTRUDA. Initial data show no safety concerns from the combination with IMP321 at 1 mg dosage. No drug related serious adverse events have been reported and the DSMB approved the continuance of the dose escalation as planned. The trial will now proceed to the next dose level of 6 mg.
Prima''s Chief Medical Officer, Dr Frédéric Triebel, said: "The majority of metastatic melanoma patients do not respond well to KEYTRUDA, a key reason being that their tumours are poorly infiltrated by activated T cells expressing PD-1. By introducing IMP321, a first-in-class Antigen Presenting Cell (APC) activator, these patients may now be able to repopulate their tumour with more activated T cells which are responsive to KEYTRUDA. So, by combining the effect of ''pushing the gas'' with IMP321 and ''releasing the brake'' with KEYTRUDA we propose a rational therapeutic approach to increase the response rate by further boosting anti-tumour CD8 T cells."
Further data updates in terms of safety and activity could be expected throughout 2017.
IMP321, a first-in-class Antigen Presenting Cell (APC) activator based on the immune checkpoint LAG-3, represents one of the first proposed active immunotherapy drugs in which the patient''s own immune system is harnessed to respond to tumour antigenic debris created by chemotherapy. As an APC activator IMP321 boosts the network of dendritic cells in the body that can respond to tumour antigens for a better anti-tumour CD8 T cell response.
Prima BioMed is listed on the Australian Securities Exchange and on the NASDAQ in the US. For further information please visit .
Matthew Beck
The Trout Group LLC
+1 (646) 378-2933
Mr Matthew Gregorowski
Citadel-MAGNUS
+61 2 8234 0105
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 29.12.2016 - 03:04 Uhr
Sprache: Deutsch
News-ID 1477912
Anzahl Zeichen: 2267
contact information:
Contact person:
Town:
SYDNEY, AUSTRALIA
Phone:
Kategorie:
Biotech
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 353 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Prima BioMed Announces First Clinical Data From Combination of IMP321 With Anti-PD1
"
steht unter der journalistisch-redaktionellen Verantwortung von
Prima BioMed Ltd (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
